Last reviewed · How we verify

Propofol, Lidocaine and fentanyl

Kasr El Aini Hospital · FDA-approved active Small molecule

This is a combination of three agents that work together: propofol (GABA agonist for sedation), lidocaine (local anesthetic blocking sodium channels), and fentanyl (opioid agonist for analgesia and sedation).

This is a combination of three agents that work together: propofol (GABA agonist for sedation), lidocaine (local anesthetic blocking sodium channels), and fentanyl (opioid agonist for analgesia and sedation). Used for Induction and maintenance of general anesthesia, Sedation for procedures and mechanical ventilation.

At a glance

Generic namePropofol, Lidocaine and fentanyl
SponsorKasr El Aini Hospital
Drug classAnesthetic combination (sedative-hypnotic, local anesthetic, opioid)
TargetGABA-A receptor (propofol), voltage-gated sodium channels (lidocaine), mu-opioid receptor (fentanyl)
ModalitySmall molecule
Therapeutic areaAnesthesiology / Sedation
PhaseFDA-approved

Mechanism of action

Propofol enhances inhibitory GABAergic neurotransmission to produce rapid sedation and hypnosis. Lidocaine blocks voltage-gated sodium channels to provide local anesthetic effects and reduce pain perception. Fentanyl binds to mu-opioid receptors to provide analgesia, anxiolysis, and potentiate sedation. Together, these agents provide balanced anesthesia with sedation, analgesia, and amnesia.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: